AndroGel and Bupropion Interaction: Safety, Risks, and Clinical Guidance

HealthRX.com

No listed interaction, but each drug has separate risks

Print or save as PDF

Key numbers

  • 0.1%Seizure rate with sustained-release bupropion up to 300 mg a day (about 1 in 1,000 people)Source: accessdata.fda.gov, as cited Nov 7, 2026
  • 0.4%Seizure rate with immediate-release bupropion at 300 to 450 mg a day (13 of 3,200 people)Source: accessdata.fda.gov, as cited Nov 7, 2026
  • 7.0%Major adverse cardiovascular events in men on testosterone gel in TRAVERSE, versus 7.3% on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026

From the public record

FDA adverse event reports listing both bupropion and testosterone

Through 2026-10-28, FDA had received 1,193 adverse event reports that list both bupropion and testosterone, out of 112,512 reports for bupropion and 41,579 for testosterone. A joint report shows both were recorded for the same person, not that they interacted.

FDA adverse event reports listing both bupropion and testosterone: the figures
MeasureValue
Reports listing both drugs1,193
All reports for bupropion112,512
All reports for testosterone41,579
Joint reports naming pain110
Joint reports naming fatigue91
Joint reports naming anxiety87
Joint reports naming nausea66

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, data as of Oct 28, 2026

How this was calculated

Counted FAERS reports that list both active substances in any role, then the symptom terms named most often in those reports. Terms about product use rather than symptoms were left out. The events may relate to either drug, to another drug, or to the illness.

Scope: Reports listing both bupropion and testosterone as single-ingredient active substances, any brand, suspect or concomitant

FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs. Joint reports are not evidence of an interaction.

Download the data (CSV)

From the public record

Published papers mentioning both testosterone and bupropion

PubMed indexes 73 papers whose title or abstract mentions both testosterone and bupropion, 26 of them published from 2016 to 2025. For comparison, 103,536 papers mention testosterone and 5,784 mention bupropion.

Published papers mentioning both testosterone and bupropion: the figures
MeasureValue
Papers mentioning both73
Of those, published 2016 to 202526
Papers mentioning testosterone103,536
Papers mentioning bupropion5,784

Source: NIH National Library of Medicine, PubMed, data as of Nov 11, 2026

How this was calculated

Ran one PubMed title and abstract search requiring both names, and one search for each name alone. No filtering by study type or quality.

Scope: PubMed records naming both substances in the title or abstract, all article types and species

A paper that mentions both is not necessarily a study of their interaction, and may report no interaction. Counts include animal, cell and review papers.

Download the data (CSV)

At a glance

  • Bupropion CYP2D6 warning covers / antidepressants, antipsychotics, beta-blockers, Type 1C antiarrhythmics [2]
  • Generic testosterone gel 1.62% label interaction list / insulin and diabetes medicines, oral anticoagulants, corticosteroids or ACTH [4]
  • Bupropion seizure risk / about 0.1% at up to 300 mg a day sustained-release; about 0.4% at 300 to 450 mg a day immediate-release [1]
  • Seizure disorder / bupropion is contraindicated [2]
  • Blood pressure / raised class-wide by testosterone products [3]; the naltrexone-bupropion label warns of blood pressure and heart rate increases [2]
  • Heart outcomes / TRAVERSE used AndroGel 1.62%: major cardiovascular events 7.0% vs 7.3% on placebo [5][6]

Is there an interaction between the two?

Bupropion inhibits CYP2D6. The Contrave (naltrexone-bupropion) label says this can raise concentrations of antidepressants including SSRIs and many tricyclics, antipsychotics such as haloperidol, risperidone and thioridazine, beta-blockers such as metoprolol, and Type 1C antiarrhythmics such as propafenone and flecainide, and says a dose reduction of those drugs should be considered [2]. Given with a single 50 mg dose of metoprolol, Contrave raised metoprolol AUC about 4-fold and peak concentration about 2-fold [2].

The generic testosterone gel 1.62% label (Padagis) has a shorter interaction list: insulin and diabetes medicines, whose requirement may fall as androgens lower blood glucose; oral anticoagulants, where the label recommends more frequent INR and prothrombin time monitoring, especially when androgen therapy is started or stopped; and corticosteroids or ACTH, which together with testosterone may increase fluid retention [4]. Bupropion is not on that list, and testosterone is not among the CYP2D6 drugs the bupropion labeling names [2]. That label is for a generic gel rather than the AndroGel brand, and topical testosterone products can differ in strength, dose and systemic exposure [4].

Questions worth asking

Choose the questions you want to keep

Does bupropion change testosterone levels?

The bupropion labeling's interaction warnings concern drugs that bupropion affects through CYP2D6 and other pathways, and testosterone is not among the drugs it names [2].

Seizure risk sits on the bupropion side

The quantified, dose-related seizure risk belongs to bupropion. About 0.1% (1 in 1,000) of people taking sustained-release bupropion up to 300 mg a day have a seizure, and about 0.4% (13 of 3,200) of those taking immediate-release bupropion at 300 to 450 mg a day; for the immediate-release form the estimated incidence rises almost tenfold between 450 and 600 mg a day [1]. Gradual titration lowers the risk [1].

The Contrave label contraindicates bupropion in anyone with a seizure disorder or a history of seizures, in bulimia or anorexia nervosa, and during abrupt withdrawal from alcohol, benzodiazepines, barbiturates or antiepileptic drugs [2]. It also says to use extreme caution with other drugs that lower the seizure threshold, naming antipsychotics, antidepressants, theophylline and systemic corticosteroids, with low initial doses and gradual increases [2].

Blood pressure can rise with both

Testosterone products raise blood pressure. FDA's February 2025 labeling action followed required ambulatory blood pressure monitoring studies and stated that the completed studies confirmed a blood pressure increase with use of all testosterone products, class-wide; the agency required a new blood pressure warning for products that lacked one and product-specific data where monitoring studies had been done [3].

Bupropion can raise blood pressure too. The Contrave label, for the naltrexone-bupropion combination, says to monitor blood pressure and heart rate in all patients, especially those with cardiac or cerebrovascular disease, and contraindicates it in uncontrolled hypertension [2].

What TRAVERSE showed for the gel

FDA describes the TRAVERSE cardiovascular safety trial as having tested AndroGel 1.62% [5]. The trial randomized 5,246 men aged 45 to 80 with hypogonadism and existing or high risk of cardiovascular disease to daily 1.62% testosterone gel or placebo gel, with mean treatment of 21.7 months and mean follow-up of 33 months. Major adverse cardiovascular events occurred in 7.0% of men on testosterone gel versus 7.3% on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17) [6]. FDA reviewed the results and said they did not demonstrate a new safety signal or trend in adverse cardiovascular outcomes [5].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the Contrave label, in which group is bupropion contraindicated?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Frequently asked questions

Can you take AndroGel with bupropion?
The Contrave labeling and the generic testosterone gel 1.62% labeling do not name the other drug as an interaction [2][4]. The effects that need attention are separate: bupropion's dose-related seizure risk and its contraindication in seizure disorder [1][2], and the class-wide blood pressure rise from testosterone products [3].
Does bupropion raise testosterone levels?
The bupropion labeling does not name testosterone among the drugs affected through CYP2D6; that list covers antidepressants, antipsychotics, beta-blockers and Type 1C antiarrhythmics [2].
Can someone with a seizure disorder take bupropion?
The Contrave label contraindicates bupropion in anyone with a seizure disorder or a history of seizures, and in bulimia or anorexia nervosa [2]. Seizure risk is dose-related: about 0.1% (1 in 1,000) with sustained-release doses up to 300 mg a day and about 0.4% (13 of 3,200) with immediate-release doses of 300 to 450 mg a day [1].
Do AndroGel and bupropion both affect blood pressure?
Yes, each separately. FDA says ambulatory blood pressure studies confirmed a blood pressure increase with all testosterone products, class-wide [3]. The Contrave label, for the naltrexone-bupropion combination, says to monitor blood pressure and heart rate in all patients, especially those with cardiac or cerebrovascular disease, and contraindicates it in uncontrolled hypertension [2].
Was AndroGel tested for cardiovascular risk?
FDA describes the TRAVERSE trial as having tested AndroGel 1.62%. It randomized 5,246 men aged 45 to 80 with hypogonadism and existing or high cardiovascular risk; major adverse cardiovascular events occurred in 7.0% on testosterone gel versus 7.3% on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17) [5][6].

References

Show all 7 referencesHide references
  1. U.S. Food and Drug Administration. Zyban (bupropion hydrochloride) prescribing information, 2017. Zyban prescribing information
  2. U.S. National Library of Medicine, DailyMed. Contrave Extended-Release (naltrexone and bupropion), Azurity (naltrexone hydrochloride and bupropion hydrochloride) prescribing information. Contrave Extended-Release (naltrexone and bupropion), Azurity (naltrexone hydrochloride and bupropion hydrochloride) label
  3. FDA issues class-wide labeling changes for testosterone products | FDA.
  4. U.S. National Library of Medicine, DailyMed. Testosterone gel 1.62% topical, generic (Padagis) prescribing information. Testosterone gel 1.62% topical, generic (Padagis) label
  5. Testosterone Information | FDA.
  6. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117.
  7. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
Evidence overview for AndroGel and Bupropion Interaction: Safety, Risks, and Clinical Guidance